Skip to content

FDA OKs early-stage study for MorphoSys/I-Mab solid tumor monoclonal antibody

September 17, 2020

MorphoSys’s (NASDAQ:MOR) and its collaborating partner, I-Mab (NASDAQ:IMAB) announce that the FDA has signed off Phase 1 trial for MOR210/TJ210 for the treatment of relapsed or refractory advanced solid tumors.

MOR210/TJ210 is a monoclonal antibody that is directed against complement factor C5a receptor 1.

The trial is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of MOR210/TJ210, and is expected to commence subsequently.

MorphoSys and I-Mab announced exclusive licensing agreement to develop and commercialize MOR210/TJ210 in November 2018, and I-Mab received exclusive rights to the compound in Greater China and South Korea, while MorphoSys retains rights in other parts of the world.

Both the companies are also collaborating on MorphoSys’ investigational human CD38 antibody MOR202/TJ202. I-Mab owns the exclusive rights for development and commercialization in mainland China, Taiwan, Hong Kong and Macao and started two registrational trials to evaluate MOR202/TJ202 in patients with relapsed or refractory multiple myeloma in 2019.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: